Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRI + panitumumab in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer
2017-001639-38Phase 2Active
- Sponsor
- GEMCAD
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by GEMCAD. Primary endpoint: Progression-free survival at one year. Started Jun 2017; status: active.
02
Drugs
panitumumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2017-001639-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001639-38.